| ǥ :
|
ȣ - 480376 26 |
| The Role of Baseline Platelet Count at the Clinical Outcomes after Successful Pecutaneous Coronary Intervention
|
| Division of Cardiology, Internal Medicine, Dongsan Medical Center, Keimyung University |
| Chang-Wook Nam, Seung-Ho Hur, Yun-Kyung Cho, Kee-Sik Kim, Kwon-Bae Kim, Mi-Sook Kang, Chang-Wook Park, Young-Soo Lee, Sang-Hoon Lee, Seong-Wook Han, Yoon-Nyun Kim |
BACKGROUND: Platelet reactivity is pivotal in the pathogenesis of complications after percutaneous coronary intervention (PCI). So, it is possible that higher baseline platelet count may exert influence on increases ischemic complications. OBJECTIVES: This study investigated the relation between baseline platelet count and the outcome of PCI. METHODS: Analyzable 691 patients (1105 lesions) who had PCI with stent since April 2001, to June 2004 were enrolled. The patients was divided into two groups according to baseline platelet count (elevated group; platelet count > 349,000. 90th percentile. n = 115). RESULTS: Clinical follow-up was available in 95.1%. Mean follow-up duration was 11.4 months. See as a following table. CONCLUSIONS: In this study, baseline elevated platelet count affected to increased risk of stroke, bypass surgery, major cardiac adverse event.
|
|
Group
(n
= patient/lesion) |
Elevated group
(n = 76/115) |
Normal group
(n = 615/990) |
p Value |
|
Male (%)
Age, yrs
DM
(%)
SA/UA/AMI (%)
1/2/3 VD
(%)
Pre-PCI
RD, mm
Lesion length, mm
Stent size, mm
Post-PCI MLD, mm
Angina/Stroke (%)
Death/Nonfatal MI (%)
CABG/TVR (%)
MACE (%)
QCA restenosis (%) |
53.9
59.9 ± 9.1
18.4
46.1/17.1/36.8
50.0/28.9/21.1
3.18 ± 0.49
17.90 ± 8.40
3.29 ± 0.43
3.16 ± 0.44
21.7/4.3
7.2/0
3.9/6.7
17.4
29.4 |
58.7
61.3 ± 10.3
19.5
44.9/18.2/36.9
48.5/33.0/18.5
3.19 ± 0.46
19.22 ± 9.43
3.25 ± 0.63
3.15 ± 0.51
15.8/0.2
1.2/1.4
0.2/4.4
6.5
22.3 |
0.251
0.220
0.481
0.967
0.740
0.905
0.175
0.520
0.819
0.140/0.004+
0.005+/0.410
0.005+/0.205
0.003+
0.173 |
DM; diabetes, VD; vessel diameter, RD; reference diameter, DS; diameter
stenosis, MLD; minimal diameter, TVR; target vessel revascularization, MACE;
major adverse cardiac event, +; p value <
0.05
|
|
|
